{
  "specVersion": "1.0",
  "host": {
    "displayName": "oncolabels",
    "identifier": "https://oncolabels.com"
  },
  "entries": [
    {
      "identifier": "urn:air:oncolabels.com:server:oncolabels",
      "displayName": "oncolabels MCP server",
      "type": "application/mcp-server-card+json",
      "url": "https://oncolabels.com/.well-known/mcp/server-card.json",
      "description": "The EU-approved indications of targeted, immune and hormone cancer drugs, read from section 4.1 of the EMA product information (SmPC). Search them by tumour, biomarker, line of therapy, setting or drug, list what to test in a tumour and compare biomarker cut-offs. Public and read-only. Every entry is generated by AI, and the current SmPC takes precedence.",
      "capabilities": [
        "search_indications",
        "what_to_test",
        "get_drug",
        "get_indication",
        "whats_new",
        "list_values"
      ],
      "representativeQueries": [
        "Which EU-approved drugs need an EGFR mutation in non-small cell lung cancer?",
        "What PD-L1 cut-off does pembrolizumab need in gastric cancer in the EU?",
        "Which biomarkers should be tested in metastatic colorectal cancer?",
        "Which cancer drug labels has EMA changed this month?"
      ]
    },
    {
      "identifier": "urn:air:oncolabels.com:api:oncolabels",
      "displayName": "oncolabels API",
      "type": "application/vnd.oai.openapi+json;version=3.1",
      "url": "https://oncolabels.com/api/v1/openapi.json",
      "description": "The EU-approved indications of targeted, immune and hormone cancer drugs, read from section 4.1 of the EMA product information (SmPC). Search them by tumour, biomarker, line of therapy, setting or drug, list what to test in a tumour and compare biomarker cut-offs. Public and read-only. Every entry is generated by AI, and the current SmPC takes precedence.",
      "capabilities": [
        "search_indications",
        "what_to_test",
        "get_drug",
        "get_indication",
        "whats_new",
        "list_values"
      ],
      "representativeQueries": [
        "Which EU-approved drugs need an EGFR mutation in non-small cell lung cancer?",
        "What PD-L1 cut-off does pembrolizumab need in gastric cancer in the EU?",
        "Which biomarkers should be tested in metastatic colorectal cancer?",
        "Which cancer drug labels has EMA changed this month?"
      ]
    },
    {
      "identifier": "urn:air:oncolabels.com:skill:oncolabels",
      "displayName": "oncolabels",
      "type": "application/agent-skills+md",
      "url": "https://oncolabels.com/.well-known/agent-skills/oncolabels/SKILL.md",
      "description": "Look up the EU-approved indications of targeted, immune and hormone cancer drugs (EMA SmPC section 4.1) through the public oncolabels API: by tumour, biomarker, line of therapy, setting or drug, what to test in a tumour, and biomarker cut-offs such as PD-L1, with the label sentence and SmPC link. Use for questions about what the EU has approved, for whom and at which cut-off.",
      "representativeQueries": [
        "Which EU-approved drugs need an EGFR mutation in non-small cell lung cancer?",
        "What PD-L1 cut-off does pembrolizumab need in gastric cancer in the EU?",
        "Which biomarkers should be tested in metastatic colorectal cancer?",
        "Which cancer drug labels has EMA changed this month?"
      ]
    }
  ]
}